Updated hourlyHourly refreshSat, Aug 8, 2026
Press Release Database
Recent press releases, indexed by topic.
Finance
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 7, 2026 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Rackspace Technology, Inc. (NASDAQ:RXT) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Rackspace securities between May 7, 2026 and July 8, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site:bgandg.com/RXT. Rackspace Case Details The ..
Aug 7 · 17:02·PR-Inside
Finance
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 7, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Phathom Pharmaceuticals, Inc. ("Phathom" or "the Company") (NASDAQ:PHAT). Investors who purchased Phathom securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site:bgandg.com/PHAT. Phathom Investigation Details Phathom announced second quarter 2026 financial results and lowered its full-year 2026 net revenue guidance to $300 million to $325 million, down from the $320 million to $345 million range that the Company had reaffirmed on its February 26, 2026 fourth quarter 2025 earnings call ..
Aug 7 · 17:02·PR-Inside
Finance · Healthcare
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 7, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Replimune Group Inc. ("Replimune" or "the Company") (NASDAQ:REPL). Investors who purchased Replimune securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site:bgandg.com/REPL. Replimune Investigation Details On July 28, 2026, the US Food and Drug Administration ("FDA") released briefing documents related to Replimune's lead trial for its drug vusolimogene oderparepvec, or RP1, for skin cancer. The briefing documents state the FDA has deemed the single-arm mid-stage study submitted by Replimune to ..
Aug 7 · 17:02·PR-Inside
Finance
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 7, 2026 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Park Ha Biological Technology Co., Ltd. (NASDAQ:BYAH) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Park Ha securities between December 27, 2024 and July 8, 2025, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the ..
Aug 7 · 17:02·PR-Inside
Finance
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 7, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dr. Reddy's Laboratories Limited ("Dr. Reddy's Laboratories" or "the Company") (NYSE:RDY). Investors who purchased Dr. Reddy's Laboratories securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site:bgandg.com/RDY. Dr. Reddy's Laboratories Investigation Details On July 22, 2026, Dr. Reddy's Laboratories reported first-quarter fiscal 2027 financial results that missed expectations and disclosed a ₹2.4 billion provision related to out-of-specification semaglutide batches. During the accompanying earnings call, Chief Executive Officer Erez Israeli stated ..
Aug 7 · 17:02·PR-Inside
Finance
New York, New York--(Newsfile Corp. - August 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hertz Global Holdings, Inc. (NASDAQ: HTZ) between May 7, 2026 and June 23, 2026, inclusive (the "Class Period"), of the important September 22, 2026 lead plaintiff deadline.SO WHAT: If you purchased Hertz common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency...
Aug 7 · 17:02·mlpr-newsfile
Finance
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 7, 2026 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Wix.com Ltd. (NASDAQ:WIX) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Wix securities between February 19, 2025 and May 12, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site:bgandg.com/WIX. Wix Case Details According to ..
Aug 7 · 17:01·PR-Inside
Finance
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 7, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agios Pharmaceuticals, Inc. ("Agios" or "the Company") (NASDAQ:AGIO). Investors who purchased Agios securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site:bgandg.com/AGIO. Agios Investigation Details On July 21, 2026, Agios issued a press release "announcing topline results from the Phase 2 trial of tebapivat, an oral pyruvate kinase (PK) activator, in patients aged 16 years or older with sickle cell disease." The press release disclosed that "[t]he trial did not ..
Aug 7 · 17:01·PR-Inside
Finance
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 7, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zevra Therapeutics, Inc. ("Zevra" or "the Company") (NASDAQ:ZVRA). Investors who purchased Zevra securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site:bgandg.com/ZVRA. Zevra Investigation Details On July 24, 2026, Zevra received a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use ("CHMP") on the Marketing Authorization Application for arimoclomol, branded Meplyffa. Following this news, Zevra's stock price dropped sharply. What's Next for Zevra Investors? If you are ..
Aug 7 · 17:01·PR-Inside
Finance
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 7, 2026 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against EquipmentShare.com Inc. (NASDAQ:EQPT) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired EquipmentShare securities: (1) pursuant to the registration statement and prospectus issued in connection with the Company's January 23, 2026 initial public offering ("IPO"); or (ii) between January 23, 2026, and June 23, ..
Aug 7 · 17:01·PR-Inside
Finance
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 7, 2026 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Hertz Global Holdings, Inc. (NASDAQ:HTZ) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Hertz securities between May 7, 2026 and June 23, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site:bgandg.com/HTZ. Hertz Case ..
Aug 7 · 17:01·PR-Inside
Finance · Energy
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 7, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pathward Financial, Inc. ("Pathward" or "the Company") (NASDAQ:CASH). Investors who purchased Pathward securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site:bgandg.com/CASH. Pathward Investigation Details On July 22, 2026, Pathward reported fiscal third-quarter 2026 results that missed expectations. The Company disclosed that nonperforming loans had surged to $275.1 million, nearly triple what analysts had estimated, tied to specific problem loans including to renewable-energy construction projects. Pathward also cut its fiscal ..
Aug 7 · 17:01·PR-Inside